Chemicals
Showing 12151–12300 of 41137 results
-
Brevianamide F is an alkaloid metabolite produced by various Streptomyces, Actinomycetes, and Aspergillus strains that has diverse biological activities.{40757,40758,40759} It inhibits growth of M. luteus and S. aureus in an inhibitory disc assay when used at a concentration of 30 μg/disc as well as the Bacille Calmette-Guerin M. bovis strain (MIC = 12.5 μg/ml).{40758,40759} Brevianamide F has antifouling activity, inhibiting attachment of B. neritina larvae to PVC plates without inducing lethality (EC50 = 6.35 μg/ml; LC50 = >200 μg/ml in paint used to coat PVC plates).{40757}
Brand:CaymanSKU:23493 - 5 mgAvailable on backorder
Brevicompanine B is a fungal metabolite originally isolated from P. brevicompactum that has plant growth and circadian rhythm regulatory activity.{48300} It inhibits hypocotyl elongation in lettuce seedlings when used at a concentration of 100 mg/L but does not inhibit elongation in rice seedlings at a concentration of 300 mg/L. Brevicompanine B (100 µM) inhibits primary root growth in Arabidopsis seedlings and disrupts the transcription of various genes involved in the regulation of plant circadian rhythm.{48301} It is active against P. falciparum with an IC50 value of 35 mg/ml.{48302}
Brand:CaymanSKU:27962 - 1 mgAvailable on backorder
Brevicompanine B is a fungal metabolite originally isolated from P. brevicompactum that has plant growth and circadian rhythm regulatory activity.{48300} It inhibits hypocotyl elongation in lettuce seedlings when used at a concentration of 100 mg/L but does not inhibit elongation in rice seedlings at a concentration of 300 mg/L. Brevicompanine B (100 µM) inhibits primary root growth in Arabidopsis seedlings and disrupts the transcription of various genes involved in the regulation of plant circadian rhythm.{48301} It is active against P. falciparum with an IC50 value of 35 mg/ml.{48302}
Brand:CaymanSKU:27962 - 5 mgAvailable on backorder
Brexpiprazole is a serotonin (5-HT) and dopamine receptor modulator that has high affinity (Ki = 1A and 5-HT2A serotonin, dopamine D2L, and α1B-, and α2C-adrenergic receptors in CHO cell membranes expressing the human receptors.{39167} It acts as a partial agonist of 5-HT1A, D2L, and D3 receptors (EC50s = 0.49, 4.0, and 2.8 nM, respectively) and an antagonist of 5-HT2A, 5-HT2B, as well as α1B- and α2C-adrenergic receptors (IC50s = 6.5, 14, 0.66, and 63 nM, respectively) in vitro. In vivo, brexpiprazole dose-dependently reduces conditioned avoidance response (CAR) time, inhibits locomoter hyperactivity induced by apomorphine (Item No. 16094) and amphetamine, and reverses cognitive defects induced by subchronic PCP administration in rats.{39168} It also reduces apomorphine-induced eye blinking in cynomolgus monkeys. Formulations containing brexpiprazole have been used in the treatment of schizophrenia and major depressive disorder.
Brand:CaymanSKU:22906 - 10 mgAvailable on backorder
Brexpiprazole is a serotonin (5-HT) and dopamine receptor modulator that has high affinity (Ki = 1A and 5-HT2A serotonin, dopamine D2L, and α1B-, and α2C-adrenergic receptors in CHO cell membranes expressing the human receptors.{39167} It acts as a partial agonist of 5-HT1A, D2L, and D3 receptors (EC50s = 0.49, 4.0, and 2.8 nM, respectively) and an antagonist of 5-HT2A, 5-HT2B, as well as α1B- and α2C-adrenergic receptors (IC50s = 6.5, 14, 0.66, and 63 nM, respectively) in vitro. In vivo, brexpiprazole dose-dependently reduces conditioned avoidance response (CAR) time, inhibits locomoter hyperactivity induced by apomorphine (Item No. 16094) and amphetamine, and reverses cognitive defects induced by subchronic PCP administration in rats.{39168} It also reduces apomorphine-induced eye blinking in cynomolgus monkeys. Formulations containing brexpiprazole have been used in the treatment of schizophrenia and major depressive disorder.
Brand:CaymanSKU:22906 - 100 mgAvailable on backorder
Brexpiprazole is a serotonin (5-HT) and dopamine receptor modulator that has high affinity (Ki = 1A and 5-HT2A serotonin, dopamine D2L, and α1B-, and α2C-adrenergic receptors in CHO cell membranes expressing the human receptors.{39167} It acts as a partial agonist of 5-HT1A, D2L, and D3 receptors (EC50s = 0.49, 4.0, and 2.8 nM, respectively) and an antagonist of 5-HT2A, 5-HT2B, as well as α1B- and α2C-adrenergic receptors (IC50s = 6.5, 14, 0.66, and 63 nM, respectively) in vitro. In vivo, brexpiprazole dose-dependently reduces conditioned avoidance response (CAR) time, inhibits locomoter hyperactivity induced by apomorphine (Item No. 16094) and amphetamine, and reverses cognitive defects induced by subchronic PCP administration in rats.{39168} It also reduces apomorphine-induced eye blinking in cynomolgus monkeys. Formulations containing brexpiprazole have been used in the treatment of schizophrenia and major depressive disorder.
Brand:CaymanSKU:22906 - 50 mgAvailable on backorder
Brexpiprazole-d8 is intended for use as an internal standard for the quantification of brexpiprazole (Item No. 22906) by GC- or LC-MS. Brexpiprazole is a serotonin (5-HT) and dopamine receptor modulator that has high affinity (Ki = 1A and 5-HT2A serotonin, dopamine D2L, and α1B-, and α2C-adrenergic receptors in CHO cell membranes expressing the human receptors.{39167} It acts as a partial agonist of 5-HT1A, D2L, and D3 receptors (EC50s = 0.49, 4.0, and 2.8 nM, respectively) and an antagonist of 5-HT2A, 5-HT2B, as well as α1B- and α2C-adrenergic receptors (IC50s = 6.5, 14, 0.66, and 63 nM, respectively) in vitro. In vivo, brexpiprazole dose-dependently reduces conditioned avoidance response (CAR) time, inhibits locomoter hyperactivity induced by apomorphine (Item No. 16094) and amphetamine, and reverses cognitive defects induced by subchronic PCP administration in rats.{39168} It also reduces apomorphine-induced eye blinking in cynomolgus monkeys. Formulations containing brexpiprazole have been used in the treatment of schizophrenia and major depressive disorder.
Brand:CaymanSKU:26450 - 1 mgAvailable on backorder
Brexpiprazole-d8 is intended for use as an internal standard for the quantification of brexpiprazole (Item No. 22906) by GC- or LC-MS. Brexpiprazole is a serotonin (5-HT) and dopamine receptor modulator that has high affinity (Ki = 1A and 5-HT2A serotonin, dopamine D2L, and α1B-, and α2C-adrenergic receptors in CHO cell membranes expressing the human receptors.{39167} It acts as a partial agonist of 5-HT1A, D2L, and D3 receptors (EC50s = 0.49, 4.0, and 2.8 nM, respectively) and an antagonist of 5-HT2A, 5-HT2B, as well as α1B- and α2C-adrenergic receptors (IC50s = 6.5, 14, 0.66, and 63 nM, respectively) in vitro. In vivo, brexpiprazole dose-dependently reduces conditioned avoidance response (CAR) time, inhibits locomoter hyperactivity induced by apomorphine (Item No. 16094) and amphetamine, and reverses cognitive defects induced by subchronic PCP administration in rats.{39168} It also reduces apomorphine-induced eye blinking in cynomolgus monkeys. Formulations containing brexpiprazole have been used in the treatment of schizophrenia and major depressive disorder.
Brand:CaymanSKU:26450 - 500 µgAvailable on backorder
Briciclib is a water soluble derivative of ON 013100, a small molecule that binds to and inhibits eukaryotic translation initiation factor 4E (eIF4E).{39361} Briciclib inhibits proliferation of JEKO-1 and Mino mantle cell leukemia (MCL), MCF-7 and MDA-MB-231 breast, AGS gastric, and OE19, OE33, and LFO-1 esophageal cancer cell lines with GI50 values ranging from 9.8 to 12.2 nM. It reduces expression of cyclin D1 and c-Myc, markers of eIF4E activity, in breast and MCL cancer cell lines in a dose-dependent manner. Briciclib also induces expression of the pro-apoptotic proteins p53 and cleaved caspase-3.
Brand:CaymanSKU:22989 - 1 mgAvailable on backorder
Briciclib is a water soluble derivative of ON 013100, a small molecule that binds to and inhibits eukaryotic translation initiation factor 4E (eIF4E).{39361} Briciclib inhibits proliferation of JEKO-1 and Mino mantle cell leukemia (MCL), MCF-7 and MDA-MB-231 breast, AGS gastric, and OE19, OE33, and LFO-1 esophageal cancer cell lines with GI50 values ranging from 9.8 to 12.2 nM. It reduces expression of cyclin D1 and c-Myc, markers of eIF4E activity, in breast and MCL cancer cell lines in a dose-dependent manner. Briciclib also induces expression of the pro-apoptotic proteins p53 and cleaved caspase-3.
Brand:CaymanSKU:22989 - 10 mgAvailable on backorder
Briciclib is a water soluble derivative of ON 013100, a small molecule that binds to and inhibits eukaryotic translation initiation factor 4E (eIF4E).{39361} Briciclib inhibits proliferation of JEKO-1 and Mino mantle cell leukemia (MCL), MCF-7 and MDA-MB-231 breast, AGS gastric, and OE19, OE33, and LFO-1 esophageal cancer cell lines with GI50 values ranging from 9.8 to 12.2 nM. It reduces expression of cyclin D1 and c-Myc, markers of eIF4E activity, in breast and MCL cancer cell lines in a dose-dependent manner. Briciclib also induces expression of the pro-apoptotic proteins p53 and cleaved caspase-3.
Brand:CaymanSKU:22989 - 25 mgAvailable on backorder
Briciclib is a water soluble derivative of ON 013100, a small molecule that binds to and inhibits eukaryotic translation initiation factor 4E (eIF4E).{39361} Briciclib inhibits proliferation of JEKO-1 and Mino mantle cell leukemia (MCL), MCF-7 and MDA-MB-231 breast, AGS gastric, and OE19, OE33, and LFO-1 esophageal cancer cell lines with GI50 values ranging from 9.8 to 12.2 nM. It reduces expression of cyclin D1 and c-Myc, markers of eIF4E activity, in breast and MCL cancer cell lines in a dose-dependent manner. Briciclib also induces expression of the pro-apoptotic proteins p53 and cleaved caspase-3.
Brand:CaymanSKU:22989 - 5 mgAvailable on backorder
Brilliant Blue G is a dye which is commonly used in laboratories to stain or quantify proteins. A variety of methods have been developed for using Brilliant Blue G to stain gels with ease and sensitivity.{22767,22770,22766,22771} The Bradford assay is a standard, rapid dye-binding assay that uses Brilliant Blue G to quantify the amount of protein in a solution.{11189} This compound also acts as a selective inhibitor of the P2X purinoceptor channel P2X7 (IC50s = 10.1 and 265 nM for rat and human P2X7, respectively).{22768} In mice, it inhibits interleukin-1β expression and reduces neurological injury secondary to traumatic brain injury.{22769}
Brand:CaymanSKU:- Brilliant Blue G is a dye which is commonly used in laboratories to stain or quantify proteins. A variety of methods have been developed for using Brilliant Blue G to stain gels with ease and sensitivity.{22767,22770,22766,22771} The Bradford assay is a standard, rapid dye-binding assay that uses Brilliant Blue G to quantify the amount of protein in a solution.{11189} This compound also acts as a selective inhibitor of the P2X purinoceptor channel P2X7 (IC50s = 10.1 and 265 nM for rat and human P2X7, respectively).{22768} In mice, it inhibits interleukin-1β expression and reduces neurological injury secondary to traumatic brain injury.{22769}
Brand:CaymanSKU:-
Brimonidine is an agonist of α2-adrenergic receptors (α2-ARs; Kis = 2.7, 52, and 44 nM for α2A, α2B, and α2C-ARs, respectively, in CHO cells).{42418} It is selective for α2-ARs over α1-ARs (Ki = 1,800 nM in human brain). Brimonidine lowers intraocular pressure in DBA/2J mice, a model of glaucoma, to control levels when applied topically to the eye as a 0.1% solution.{42419} It also inhibits glutamate release, prevents upregulation of NMDA receptors containing NR1 and NR2A subunits, and protects rat retinal ganglion cells against glutamate excitotoxicity in a rat model of retinal ischemia when administered at a dose of 1 mg/kg per day.{25329} Formulations containing brimonidine have been used in the treatment of open-angle glaucoma and ocular hypertension.
Brand:CaymanSKU:- Brimonidine is an agonist of α2-adrenergic receptors (α2-ARs; Kis = 2.7, 52, and 44 nM for α2A, α2B, and α2C-ARs, respectively, in CHO cells).{42418} It is selective for α2-ARs over α1-ARs (Ki = 1,800 nM in human brain). Brimonidine lowers intraocular pressure in DBA/2J mice, a model of glaucoma, to control levels when applied topically to the eye as a 0.1% solution.{42419} It also inhibits glutamate release, prevents upregulation of NMDA receptors containing NR1 and NR2A subunits, and protects rat retinal ganglion cells against glutamate excitotoxicity in a rat model of retinal ischemia when administered at a dose of 1 mg/kg per day.{25329} Formulations containing brimonidine have been used in the treatment of open-angle glaucoma and ocular hypertension.
Brand:CaymanSKU:- Brimonidine is an agonist of α2-adrenergic receptors (α2-ARs; Kis = 2.7, 52, and 44 nM for α2A, α2B, and α2C-ARs, respectively, in CHO cells).{42418} It is selective for α2-ARs over α1-ARs (Ki = 1,800 nM in human brain). Brimonidine lowers intraocular pressure in DBA/2J mice, a model of glaucoma, to control levels when applied topically to the eye as a 0.1% solution.{42419} It also inhibits glutamate release, prevents upregulation of NMDA receptors containing NR1 and NR2A subunits, and protects rat retinal ganglion cells against glutamate excitotoxicity in a rat model of retinal ischemia when administered at a dose of 1 mg/kg per day.{25329} Formulations containing brimonidine have been used in the treatment of open-angle glaucoma and ocular hypertension.
Brand:CaymanSKU:- Brimonidine is an agonist of α2-adrenergic receptors (α2-ARs; Kis = 2.7, 52, and 44 nM for α2A, α2B, and α2C-ARs, respectively, in CHO cells).{42418} It is selective for α2-ARs over α1-ARs (Ki = 1,800 nM in human brain). Brimonidine lowers intraocular pressure in DBA/2J mice, a model of glaucoma, to control levels when applied topically to the eye as a 0.1% solution.{42419} It also inhibits glutamate release, prevents upregulation of NMDA receptors containing NR1 and NR2A subunits, and protects rat retinal ganglion cells against glutamate excitotoxicity in a rat model of retinal ischemia when administered at a dose of 1 mg/kg per day.{25329} Formulations containing brimonidine have been used in the treatment of open-angle glaucoma and ocular hypertension.
Brand:CaymanSKU:-
Brimonidine-d4 is intended for use as an internal standard for the quantification of brimonidine (Item No. 15426) by GC- or LC-MS. Brimonidine is an agonist of α2-adrenergic receptors (α2-ARs; Kis = 2.7, 52, and 44 nM for α2A, α2B, and α2C-ARs, respectively, in CHO cells).{42418} It is selective for α2-ARs over α1-ARs (Ki = 1,800 nM in human brain). Brimonidine lowers intraocular pressure in DBA/2J mice, a model of glaucoma, to control levels when applied topically to the eye as a 0.1% solution.{42419} It also inhibits glutamate release, prevents upregulation of NMDA receptors containing NR1 and NR2A subunits, and protects rat retinal ganglion cells against glutamate excitotoxicity in a rat model of retinal ischemia when administered at a dose of 1 mg/kg per day.{25329} Formulations containing brimonidine have been used in the treatment of open-angle glaucoma and ocular hypertension.
Brand:CaymanSKU:25465 - 1 mgAvailable on backorder
Brimonidine-d4 is intended for use as an internal standard for the quantification of brimonidine (Item No. 15426) by GC- or LC-MS. Brimonidine is an agonist of α2-adrenergic receptors (α2-ARs; Kis = 2.7, 52, and 44 nM for α2A, α2B, and α2C-ARs, respectively, in CHO cells).{42418} It is selective for α2-ARs over α1-ARs (Ki = 1,800 nM in human brain). Brimonidine lowers intraocular pressure in DBA/2J mice, a model of glaucoma, to control levels when applied topically to the eye as a 0.1% solution.{42419} It also inhibits glutamate release, prevents upregulation of NMDA receptors containing NR1 and NR2A subunits, and protects rat retinal ganglion cells against glutamate excitotoxicity in a rat model of retinal ischemia when administered at a dose of 1 mg/kg per day.{25329} Formulations containing brimonidine have been used in the treatment of open-angle glaucoma and ocular hypertension.
Brand:CaymanSKU:25465 - 5 mgAvailable on backorder
Brimonidine-d4 is intended for use as an internal standard for the quantification of brimonidine (Item No. 15426) by GC- or LC-MS. Brimonidine is an agonist of α2-adrenergic receptors (α2-ARs; Kis = 2.7, 52, and 44 nM for α2A, α2B, and α2C-ARs, respectively, in CHO cells).{42418} It is selective for α2-ARs over α1-ARs (Ki = 1,800 nM in human brain). Brimonidine lowers intraocular pressure in DBA/2J mice, a model of glaucoma, to control levels when applied topically to the eye as a 0.1% solution.{42419} It also inhibits glutamate release, prevents upregulation of NMDA receptors containing NR1 and NR2A subunits, and protects rat retinal ganglion cells against glutamate excitotoxicity in a rat model of retinal ischemia when administered at a dose of 1 mg/kg per day.{25329} Formulations containing brimonidine have been used in the treatment of open-angle glaucoma and ocular hypertension.
Brand:CaymanSKU:25465 - 500 µgAvailable on backorder
Brinzolamide is a potent inhibitor of carbonic anhydrase II (CAII) and CAIV (IC50s = 3.19 and 45.3 nM, respectively).{53202} It is selective for CAII and CAIV over CAI (IC50 = ~1,365 nM). Brinzolamide (30 mg/kg) reduces intestinal charcoal meal progression by 44% and prolongs pentobarbital sodium-induced sleep time by 35% in mice. Topical administration of brinzolamide (0.25, 0.5, and 1 mg/eye) reduces intraocular pressure (IOP) in a rabbit model of spontaneous ocular hypertension. It also reduces IOP in a cynomolgus monkey model of argon laser trabeculoplasty-induced ocular hypertension. Formulations containing brinzolamide have been used in the treatment of glaucoma and ocular hypertension.
Brand:CaymanSKU:11660 - 10 mgAvailable on backorder
Brinzolamide is a potent inhibitor of carbonic anhydrase II (CAII) and CAIV (IC50s = 3.19 and 45.3 nM, respectively).{53202} It is selective for CAII and CAIV over CAI (IC50 = ~1,365 nM). Brinzolamide (30 mg/kg) reduces intestinal charcoal meal progression by 44% and prolongs pentobarbital sodium-induced sleep time by 35% in mice. Topical administration of brinzolamide (0.25, 0.5, and 1 mg/eye) reduces intraocular pressure (IOP) in a rabbit model of spontaneous ocular hypertension. It also reduces IOP in a cynomolgus monkey model of argon laser trabeculoplasty-induced ocular hypertension. Formulations containing brinzolamide have been used in the treatment of glaucoma and ocular hypertension.
Brand:CaymanSKU:11660 - 100 mgAvailable on backorder
Brinzolamide is a potent inhibitor of carbonic anhydrase II (CAII) and CAIV (IC50s = 3.19 and 45.3 nM, respectively).{53202} It is selective for CAII and CAIV over CAI (IC50 = ~1,365 nM). Brinzolamide (30 mg/kg) reduces intestinal charcoal meal progression by 44% and prolongs pentobarbital sodium-induced sleep time by 35% in mice. Topical administration of brinzolamide (0.25, 0.5, and 1 mg/eye) reduces intraocular pressure (IOP) in a rabbit model of spontaneous ocular hypertension. It also reduces IOP in a cynomolgus monkey model of argon laser trabeculoplasty-induced ocular hypertension. Formulations containing brinzolamide have been used in the treatment of glaucoma and ocular hypertension.
Brand:CaymanSKU:11660 - 5 mgAvailable on backorder
Brinzolamide is a potent inhibitor of carbonic anhydrase II (CAII) and CAIV (IC50s = 3.19 and 45.3 nM, respectively).{53202} It is selective for CAII and CAIV over CAI (IC50 = ~1,365 nM). Brinzolamide (30 mg/kg) reduces intestinal charcoal meal progression by 44% and prolongs pentobarbital sodium-induced sleep time by 35% in mice. Topical administration of brinzolamide (0.25, 0.5, and 1 mg/eye) reduces intraocular pressure (IOP) in a rabbit model of spontaneous ocular hypertension. It also reduces IOP in a cynomolgus monkey model of argon laser trabeculoplasty-induced ocular hypertension. Formulations containing brinzolamide have been used in the treatment of glaucoma and ocular hypertension.
Brand:CaymanSKU:11660 - 50 mgAvailable on backorder
Brinzolamide-d5 is intended for use as an internal standard for the quantification of brinzolamide (Item No. 11660) by GC- or LC-MS. Brinzolamide is a potent inhibitor of carbonic anhydrase II (CAII) and CAIV (IC50s = 3.19 and 45.3 nM, respectively).{53202} It is selective for CAII and CAIV over CAI (IC50 = ~1,365 nM). Brinzolamide (30 mg/kg) reduces intestinal charcoal meal progression by 44% and prolongs pentobarbital sodium-induced sleep time by 35% in mice. Topical administration of brinzolamide (0.25, 0.5, and 1 mg/eye) reduces intraocular pressure in a rabbit model of spontaneous ocular hypertension. It also reduces intraocular pressure in a cynomolgus monkey model of argon laser trabeculoplasty-induced ocular hypertension. Formulations containing brinzolamide have been used in the treatment of glaucoma and ocular hypertension.
Brand:CaymanSKU:30006 - 1 mgAvailable on backorder
Brinzolamide-d5 is intended for use as an internal standard for the quantification of brinzolamide (Item No. 11660) by GC- or LC-MS. Brinzolamide is a potent inhibitor of carbonic anhydrase II (CAII) and CAIV (IC50s = 3.19 and 45.3 nM, respectively).{53202} It is selective for CAII and CAIV over CAI (IC50 = ~1,365 nM). Brinzolamide (30 mg/kg) reduces intestinal charcoal meal progression by 44% and prolongs pentobarbital sodium-induced sleep time by 35% in mice. Topical administration of brinzolamide (0.25, 0.5, and 1 mg/eye) reduces intraocular pressure in a rabbit model of spontaneous ocular hypertension. It also reduces intraocular pressure in a cynomolgus monkey model of argon laser trabeculoplasty-induced ocular hypertension. Formulations containing brinzolamide have been used in the treatment of glaucoma and ocular hypertension.
Brand:CaymanSKU:30006 - 500 µgAvailable on backorder
Brivanib is an ATP-competitive inhibitor of human vascular endothelial growth factor receptors (VEGFRs) 1 and 2 and fibroblast growth factor receptor 1 (FGFR1; IC50s = 380, 25, and 148 nM, respectively, for the human recombinant proteins).{36328} It is selective for VEGFR1 and 2 and FGFR1 over PDGFRβ, EGFR, LCK, PKCα, and JAK3 (IC50s = >1,900 nM), however, it also inhibits recombinant mouse Flk1 with an IC50 value of 89 nM. In vitro, brivanib inhibits VEGF- and FGF-stimulated proliferation of human umbilical vein endothelial cells (HUVECs) with IC50 values of 40 and 276 nM, respectively. In vivo, brivanib inhibits tumor growth by 85% and 97% when administered at 60 and 90 mg/kg p.o., respectively, for 10 days in an H3396 breast cancer mouse xenograft model. Brivanib (25 mg/kg per day for 7 days, p.o.) inhibits bile duct ligation-induced liver fibrosis in mice and increases expression of PDGFβ, PDGFRβ, TGF-β1, TGF-β R2, FGF2, FGFR2, and VEGFR2 mRNAs.{36329}
Brand:CaymanSKU:23690 - 1 mgAvailable on backorder
Brivanib is an ATP-competitive inhibitor of human vascular endothelial growth factor receptors (VEGFRs) 1 and 2 and fibroblast growth factor receptor 1 (FGFR1; IC50s = 380, 25, and 148 nM, respectively, for the human recombinant proteins).{36328} It is selective for VEGFR1 and 2 and FGFR1 over PDGFRβ, EGFR, LCK, PKCα, and JAK3 (IC50s = >1,900 nM), however, it also inhibits recombinant mouse Flk1 with an IC50 value of 89 nM. In vitro, brivanib inhibits VEGF- and FGF-stimulated proliferation of human umbilical vein endothelial cells (HUVECs) with IC50 values of 40 and 276 nM, respectively. In vivo, brivanib inhibits tumor growth by 85% and 97% when administered at 60 and 90 mg/kg p.o., respectively, for 10 days in an H3396 breast cancer mouse xenograft model. Brivanib (25 mg/kg per day for 7 days, p.o.) inhibits bile duct ligation-induced liver fibrosis in mice and increases expression of PDGFβ, PDGFRβ, TGF-β1, TGF-β R2, FGF2, FGFR2, and VEGFR2 mRNAs.{36329}
Brand:CaymanSKU:23690 - 10 mgAvailable on backorder
Brivanib is an ATP-competitive inhibitor of human vascular endothelial growth factor receptors (VEGFRs) 1 and 2 and fibroblast growth factor receptor 1 (FGFR1; IC50s = 380, 25, and 148 nM, respectively, for the human recombinant proteins).{36328} It is selective for VEGFR1 and 2 and FGFR1 over PDGFRβ, EGFR, LCK, PKCα, and JAK3 (IC50s = >1,900 nM), however, it also inhibits recombinant mouse Flk1 with an IC50 value of 89 nM. In vitro, brivanib inhibits VEGF- and FGF-stimulated proliferation of human umbilical vein endothelial cells (HUVECs) with IC50 values of 40 and 276 nM, respectively. In vivo, brivanib inhibits tumor growth by 85% and 97% when administered at 60 and 90 mg/kg p.o., respectively, for 10 days in an H3396 breast cancer mouse xenograft model. Brivanib (25 mg/kg per day for 7 days, p.o.) inhibits bile duct ligation-induced liver fibrosis in mice and increases expression of PDGFβ, PDGFRβ, TGF-β1, TGF-β R2, FGF2, FGFR2, and VEGFR2 mRNAs.{36329}
Brand:CaymanSKU:23690 - 25 mgAvailable on backorder
Brivanib is an ATP-competitive inhibitor of human vascular endothelial growth factor receptors (VEGFRs) 1 and 2 and fibroblast growth factor receptor 1 (FGFR1; IC50s = 380, 25, and 148 nM, respectively, for the human recombinant proteins).{36328} It is selective for VEGFR1 and 2 and FGFR1 over PDGFRβ, EGFR, LCK, PKCα, and JAK3 (IC50s = >1,900 nM), however, it also inhibits recombinant mouse Flk1 with an IC50 value of 89 nM. In vitro, brivanib inhibits VEGF- and FGF-stimulated proliferation of human umbilical vein endothelial cells (HUVECs) with IC50 values of 40 and 276 nM, respectively. In vivo, brivanib inhibits tumor growth by 85% and 97% when administered at 60 and 90 mg/kg p.o., respectively, for 10 days in an H3396 breast cancer mouse xenograft model. Brivanib (25 mg/kg per day for 7 days, p.o.) inhibits bile duct ligation-induced liver fibrosis in mice and increases expression of PDGFβ, PDGFRβ, TGF-β1, TGF-β R2, FGF2, FGFR2, and VEGFR2 mRNAs.{36329}
Brand:CaymanSKU:23690 - 5 mgAvailable on backorder
Brivanib alaninate is the L-alanine prodrug form of brivanib (Item No. 23690), a VEGF receptor 2 (VEGFR2) and FGF receptor 1 (FGFR1) inhibitor.{36328,47106} Brivanib alaninate (3 mg/kg per day) reduces hepatic angiogenesis and VEGF, TGF-β1, CD31, and phosphorylated VEGFR2 and FGFR levels in a bile duct-ligated rat model of cirrhosis.{47107} It reduces tumor growth in an L2987 non-small cell lung cancer mouse xenograft model, exhibiting 97% tumor growth inhibition when administered at a dose of 107 mg/kg.{47106}
Brand:CaymanSKU:26081 - 10 mgAvailable on backorder
Brivanib alaninate is the L-alanine prodrug form of brivanib (Item No. 23690), a VEGF receptor 2 (VEGFR2) and FGF receptor 1 (FGFR1) inhibitor.{36328,47106} Brivanib alaninate (3 mg/kg per day) reduces hepatic angiogenesis and VEGF, TGF-β1, CD31, and phosphorylated VEGFR2 and FGFR levels in a bile duct-ligated rat model of cirrhosis.{47107} It reduces tumor growth in an L2987 non-small cell lung cancer mouse xenograft model, exhibiting 97% tumor growth inhibition when administered at a dose of 107 mg/kg.{47106}
Brand:CaymanSKU:26081 - 25 mgAvailable on backorder
Brivanib alaninate is the L-alanine prodrug form of brivanib (Item No. 23690), a VEGF receptor 2 (VEGFR2) and FGF receptor 1 (FGFR1) inhibitor.{36328,47106} Brivanib alaninate (3 mg/kg per day) reduces hepatic angiogenesis and VEGF, TGF-β1, CD31, and phosphorylated VEGFR2 and FGFR levels in a bile duct-ligated rat model of cirrhosis.{47107} It reduces tumor growth in an L2987 non-small cell lung cancer mouse xenograft model, exhibiting 97% tumor growth inhibition when administered at a dose of 107 mg/kg.{47106}
Brand:CaymanSKU:26081 - 5 mgAvailable on backorder
Brivanib alaninate is the L-alanine prodrug form of brivanib (Item No. 23690), a VEGF receptor 2 (VEGFR2) and FGF receptor 1 (FGFR1) inhibitor.{36328,47106} Brivanib alaninate (3 mg/kg per day) reduces hepatic angiogenesis and VEGF, TGF-β1, CD31, and phosphorylated VEGFR2 and FGFR levels in a bile duct-ligated rat model of cirrhosis.{47107} It reduces tumor growth in an L2987 non-small cell lung cancer mouse xenograft model, exhibiting 97% tumor growth inhibition when administered at a dose of 107 mg/kg.{47106}
Brand:CaymanSKU:26081 - 50 mgAvailable on backorder
Brivudine is a thymidine analog and inhibitor of herpes simplex virus 1 (HSV-1) and varicella-zoster virus (VZV) viral replication.{42575,53248} Following conversion to a 5′-triphosphate form by viral kinases, brivudine is incorporated into viral DNA, inhibiting viral DNA polymerases and inducing strand breakage.{53248} Brivudine (0.02-0.04 μg/ml) inhibits VZV replication in primary human fibroblasts and inhibits cytopathogenic effects of the KOS HSV-1 strain in a panel of cell lines (MIC50s = 0.007-0.4 μg/ml).{42575,53249} It selectively inhibits cytopathogenicity induced by HSV-1 strains over HSV-2, vaccinia virus, vesicular stomatitis virus, or deoxythymidine kinase-deficient HSV-1 strains in E6SM cells (MIC50s = 0.02, 2-10, 7, >400, and 40 μg/ml, respectively).{42575} Brivudine (5 and 15 mg/kg twice per day) increases survival in a mouse model of disseminated HSV-1 infection.
Brand:CaymanSKU:29448 - 1 gAvailable on backorder
Brivudine is a thymidine analog and inhibitor of herpes simplex virus 1 (HSV-1) and varicella-zoster virus (VZV) viral replication.{42575,53248} Following conversion to a 5′-triphosphate form by viral kinases, brivudine is incorporated into viral DNA, inhibiting viral DNA polymerases and inducing strand breakage.{53248} Brivudine (0.02-0.04 μg/ml) inhibits VZV replication in primary human fibroblasts and inhibits cytopathogenic effects of the KOS HSV-1 strain in a panel of cell lines (MIC50s = 0.007-0.4 μg/ml).{42575,53249} It selectively inhibits cytopathogenicity induced by HSV-1 strains over HSV-2, vaccinia virus, vesicular stomatitis virus, or deoxythymidine kinase-deficient HSV-1 strains in E6SM cells (MIC50s = 0.02, 2-10, 7, >400, and 40 μg/ml, respectively).{42575} Brivudine (5 and 15 mg/kg twice per day) increases survival in a mouse model of disseminated HSV-1 infection.
Brand:CaymanSKU:29448 - 100 mgAvailable on backorder
Brivudine is a thymidine analog and inhibitor of herpes simplex virus 1 (HSV-1) and varicella-zoster virus (VZV) viral replication.{42575,53248} Following conversion to a 5′-triphosphate form by viral kinases, brivudine is incorporated into viral DNA, inhibiting viral DNA polymerases and inducing strand breakage.{53248} Brivudine (0.02-0.04 μg/ml) inhibits VZV replication in primary human fibroblasts and inhibits cytopathogenic effects of the KOS HSV-1 strain in a panel of cell lines (MIC50s = 0.007-0.4 μg/ml).{42575,53249} It selectively inhibits cytopathogenicity induced by HSV-1 strains over HSV-2, vaccinia virus, vesicular stomatitis virus, or deoxythymidine kinase-deficient HSV-1 strains in E6SM cells (MIC50s = 0.02, 2-10, 7, >400, and 40 μg/ml, respectively).{42575} Brivudine (5 and 15 mg/kg twice per day) increases survival in a mouse model of disseminated HSV-1 infection.
Brand:CaymanSKU:29448 - 250 mgAvailable on backorder
Brivudine is a thymidine analog and inhibitor of herpes simplex virus 1 (HSV-1) and varicella-zoster virus (VZV) viral replication.{42575,53248} Following conversion to a 5′-triphosphate form by viral kinases, brivudine is incorporated into viral DNA, inhibiting viral DNA polymerases and inducing strand breakage.{53248} Brivudine (0.02-0.04 μg/ml) inhibits VZV replication in primary human fibroblasts and inhibits cytopathogenic effects of the KOS HSV-1 strain in a panel of cell lines (MIC50s = 0.007-0.4 μg/ml).{42575,53249} It selectively inhibits cytopathogenicity induced by HSV-1 strains over HSV-2, vaccinia virus, vesicular stomatitis virus, or deoxythymidine kinase-deficient HSV-1 strains in E6SM cells (MIC50s = 0.02, 2-10, 7, >400, and 40 μg/ml, respectively).{42575} Brivudine (5 and 15 mg/kg twice per day) increases survival in a mouse model of disseminated HSV-1 infection.
Brand:CaymanSKU:29448 - 500 mgAvailable on backorder
BRL 15572 is an antagonist of the serotonin (5-HT) receptor subtype 5-HT1D (Ki = 0.013 µM in CHO cell membranes expressing the human receptor).{54405} It is selective for 5-HT1D over several other G protein-coupled 5-HT receptor subtypes with Ki values ranging from 0.25 to 6.3 µM but does bind 5-HT1A and 5-HT2B receptors (Kis = 0.02 and 0.04 µM, respectively). BRL 15572 also acts as a partial agonist at 5-HT1D receptors (EC50 = 0.008 µM in a [35S]GTPγS binding assay).
Brand:CaymanSKU:31191 - 10 mgAvailable on backorder
BRL 15572 is an antagonist of the serotonin (5-HT) receptor subtype 5-HT1D (Ki = 0.013 µM in CHO cell membranes expressing the human receptor).{54405} It is selective for 5-HT1D over several other G protein-coupled 5-HT receptor subtypes with Ki values ranging from 0.25 to 6.3 µM but does bind 5-HT1A and 5-HT2B receptors (Kis = 0.02 and 0.04 µM, respectively). BRL 15572 also acts as a partial agonist at 5-HT1D receptors (EC50 = 0.008 µM in a [35S]GTPγS binding assay).
Brand:CaymanSKU:31191 - 100 mgAvailable on backorder
BRL 15572 is an antagonist of the serotonin (5-HT) receptor subtype 5-HT1D (Ki = 0.013 µM in CHO cell membranes expressing the human receptor).{54405} It is selective for 5-HT1D over several other G protein-coupled 5-HT receptor subtypes with Ki values ranging from 0.25 to 6.3 µM but does bind 5-HT1A and 5-HT2B receptors (Kis = 0.02 and 0.04 µM, respectively). BRL 15572 also acts as a partial agonist at 5-HT1D receptors (EC50 = 0.008 µM in a [35S]GTPγS binding assay).
Brand:CaymanSKU:31191 - 5 mgAvailable on backorder
BRL 15572 is an antagonist of the serotonin (5-HT) receptor subtype 5-HT1D (Ki = 0.013 µM in CHO cell membranes expressing the human receptor).{54405} It is selective for 5-HT1D over several other G protein-coupled 5-HT receptor subtypes with Ki values ranging from 0.25 to 6.3 µM but does bind 5-HT1A and 5-HT2B receptors (Kis = 0.02 and 0.04 µM, respectively). BRL 15572 also acts as a partial agonist at 5-HT1D receptors (EC50 = 0.008 µM in a [35S]GTPγS binding assay).
Brand:CaymanSKU:31191 - 50 mgAvailable on backorder
BRL 37344 is a selective agonist of β3-adrenergic receptors with Ki values of 0.43, 9.17, and 37.9 µM for β3, β2, and β1, respectively.{25395} β3-Adrenoceptors are expressed in adipose tissue as well as endothelial and myocardial tissues.{30103} This compound has been used to explore the role of these receptors in the regulation of thermogenesis and lipolysis and to modulate cardiac function in models of cardiovascular disease.{30104} It has also been used in rodents to study the role that β3-adrenergic receptors play in regulating anxiety-like behaviors.{30102}
Brand:CaymanSKU:-Available on backorder
BRL 37344 is a selective agonist of β3-adrenergic receptors with Ki values of 0.43, 9.17, and 37.9 µM for β3, β2, and β1, respectively.{25395} β3-Adrenoceptors are expressed in adipose tissue as well as endothelial and myocardial tissues.{30103} This compound has been used to explore the role of these receptors in the regulation of thermogenesis and lipolysis and to modulate cardiac function in models of cardiovascular disease.{30104} It has also been used in rodents to study the role that β3-adrenergic receptors play in regulating anxiety-like behaviors.{30102}
Brand:CaymanSKU:-Available on backorder
BRL 37344 is a selective agonist of β3-adrenergic receptors with Ki values of 0.43, 9.17, and 37.9 µM for β3, β2, and β1, respectively.{25395} β3-Adrenoceptors are expressed in adipose tissue as well as endothelial and myocardial tissues.{30103} This compound has been used to explore the role of these receptors in the regulation of thermogenesis and lipolysis and to modulate cardiac function in models of cardiovascular disease.{30104} It has also been used in rodents to study the role that β3-adrenergic receptors play in regulating anxiety-like behaviors.{30102}
Brand:CaymanSKU:-Available on backorder
BRL 37344 is a selective agonist of β3-adrenergic receptors with Ki values of 0.43, 9.17, and 37.9 µM for β3, β2, and β1, respectively.{25395} β3-Adrenoceptors are expressed in adipose tissue as well as endothelial and myocardial tissues.{30103} This compound has been used to explore the role of these receptors in the regulation of thermogenesis and lipolysis and to modulate cardiac function in models of cardiovascular disease.{30104} It has also been used in rodents to study the role that β3-adrenergic receptors play in regulating anxiety-like behaviors.{30102}
Brand:CaymanSKU:-Available on backorder
BRL 44408 is an antagonist of α2A-adrenergic receptors (α2A-ARs; Ki = 8.56 nM for the recombinant human receptors).{45714} It is greater than 50-fold selective for α2A-ARs over α1-, α2B-, α2C-, β1-, and β2-ARs, as well as 19 other neurotransmitter receptors, transporters, and enzymes in a panel at 1 µM. BRL 44408 inhibits forskolin-stimulated cAMP accumulation with an IC50 value of 92.3 nM in CHO cells expressing the recombinant human α2A-AR. It increases norepinephrine and dopamine levels by 200 and 100%, respectively, in rat medial prefrontal cortex when administered at a dose of 10 mg/kg. BRL 44408 (10 and 30 mg/kg) decreases the time rats spend immobile in the forced swim test, indicating antidepressant-like activity, and reduces para-phenylquinone-induced abdominal stretching, indicating analgesic activity, in rats.
Brand:CaymanSKU:29454 - 10 mgAvailable on backorder
BRL 44408 is an antagonist of α2A-adrenergic receptors (α2A-ARs; Ki = 8.56 nM for the recombinant human receptors).{45714} It is greater than 50-fold selective for α2A-ARs over α1-, α2B-, α2C-, β1-, and β2-ARs, as well as 19 other neurotransmitter receptors, transporters, and enzymes in a panel at 1 µM. BRL 44408 inhibits forskolin-stimulated cAMP accumulation with an IC50 value of 92.3 nM in CHO cells expressing the recombinant human α2A-AR. It increases norepinephrine and dopamine levels by 200 and 100%, respectively, in rat medial prefrontal cortex when administered at a dose of 10 mg/kg. BRL 44408 (10 and 30 mg/kg) decreases the time rats spend immobile in the forced swim test, indicating antidepressant-like activity, and reduces para-phenylquinone-induced abdominal stretching, indicating analgesic activity, in rats.
Brand:CaymanSKU:29454 - 25 mgAvailable on backorder
BRL 44408 is an antagonist of α2A-adrenergic receptors (α2A-ARs; Ki = 8.56 nM for the recombinant human receptors).{45714} It is greater than 50-fold selective for α2A-ARs over α1-, α2B-, α2C-, β1-, and β2-ARs, as well as 19 other neurotransmitter receptors, transporters, and enzymes in a panel at 1 µM. BRL 44408 inhibits forskolin-stimulated cAMP accumulation with an IC50 value of 92.3 nM in CHO cells expressing the recombinant human α2A-AR. It increases norepinephrine and dopamine levels by 200 and 100%, respectively, in rat medial prefrontal cortex when administered at a dose of 10 mg/kg. BRL 44408 (10 and 30 mg/kg) decreases the time rats spend immobile in the forced swim test, indicating antidepressant-like activity, and reduces para-phenylquinone-induced abdominal stretching, indicating analgesic activity, in rats.
Brand:CaymanSKU:29454 - 5 mgAvailable on backorder
BRL 50481 is a potent, selective inhibitor of phosphodiesterase (PDE) 7, inhibiting human recombinant PDE7A1 with a Ki value of 180 nM.{27633} It is much less effective against PDE3 and PDE4 and is without effect against PDE1B, PDE1C, PDE2, and PDE5.{27633} Through its effects on PDE7A1, BRL 50481 enhances the inhibitory effects of the PDE4 blocker rolipram (Item No. 10011132) on monocytes, lung macrophages, and CD8+ T-lymphocytes.{27633} BRL 50481, at 30 µM, promotes apoptosis in chronic lymphocytic leukemia cells overexpressing PDE7B, suggesting that this compound also acts against PDE7B.{27635} BRL 50481 can be used to evaluate the role of PDE7 isoforms in intracellular signaling.{27634}
Brand:CaymanSKU:-Out of stock
BRL 50481 is a potent, selective inhibitor of phosphodiesterase (PDE) 7, inhibiting human recombinant PDE7A1 with a Ki value of 180 nM.{27633} It is much less effective against PDE3 and PDE4 and is without effect against PDE1B, PDE1C, PDE2, and PDE5.{27633} Through its effects on PDE7A1, BRL 50481 enhances the inhibitory effects of the PDE4 blocker rolipram (Item No. 10011132) on monocytes, lung macrophages, and CD8+ T-lymphocytes.{27633} BRL 50481, at 30 µM, promotes apoptosis in chronic lymphocytic leukemia cells overexpressing PDE7B, suggesting that this compound also acts against PDE7B.{27635} BRL 50481 can be used to evaluate the role of PDE7 isoforms in intracellular signaling.{27634}
Brand:CaymanSKU:-Out of stock
BRL 50481 is a potent, selective inhibitor of phosphodiesterase (PDE) 7, inhibiting human recombinant PDE7A1 with a Ki value of 180 nM.{27633} It is much less effective against PDE3 and PDE4 and is without effect against PDE1B, PDE1C, PDE2, and PDE5.{27633} Through its effects on PDE7A1, BRL 50481 enhances the inhibitory effects of the PDE4 blocker rolipram (Item No. 10011132) on monocytes, lung macrophages, and CD8+ T-lymphocytes.{27633} BRL 50481, at 30 µM, promotes apoptosis in chronic lymphocytic leukemia cells overexpressing PDE7B, suggesting that this compound also acts against PDE7B.{27635} BRL 50481 can be used to evaluate the role of PDE7 isoforms in intracellular signaling.{27634}
Brand:CaymanSKU:-Out of stock
BRL 50481 is a potent, selective inhibitor of phosphodiesterase (PDE) 7, inhibiting human recombinant PDE7A1 with a Ki value of 180 nM.{27633} It is much less effective against PDE3 and PDE4 and is without effect against PDE1B, PDE1C, PDE2, and PDE5.{27633} Through its effects on PDE7A1, BRL 50481 enhances the inhibitory effects of the PDE4 blocker rolipram (Item No. 10011132) on monocytes, lung macrophages, and CD8+ T-lymphocytes.{27633} BRL 50481, at 30 µM, promotes apoptosis in chronic lymphocytic leukemia cells overexpressing PDE7B, suggesting that this compound also acts against PDE7B.{27635} BRL 50481 can be used to evaluate the role of PDE7 isoforms in intracellular signaling.{27634}
Brand:CaymanSKU:-Out of stock
BRL 54443 is a potent agonist of the serotonin (5-HT) receptor subtypes 5-HT1E and 5-HT1F (Ki values are 1.1 and 0.7 nM, respectively).{33346} It displays more than 30-fold selectivity over other 5-HT and dopamine receptors. At higher concentrations, BRL 54443 induces 5-HT2A-mediated contraction of mouse thoracic aorta strips in vitro (pEC50 = 6.5).{33347} It significantly reduces formalin-induced pain in rat hind paw.{33345}
Brand:CaymanSKU:21263 -Out of stock
BRL 54443 is a potent agonist of the serotonin (5-HT) receptor subtypes 5-HT1E and 5-HT1F (Ki values are 1.1 and 0.7 nM, respectively).{33346} It displays more than 30-fold selectivity over other 5-HT and dopamine receptors. At higher concentrations, BRL 54443 induces 5-HT2A-mediated contraction of mouse thoracic aorta strips in vitro (pEC50 = 6.5).{33347} It significantly reduces formalin-induced pain in rat hind paw.{33345}
Brand:CaymanSKU:21263 -Out of stock
BRL 54443 is a potent agonist of the serotonin (5-HT) receptor subtypes 5-HT1E and 5-HT1F (Ki values are 1.1 and 0.7 nM, respectively).{33346} It displays more than 30-fold selectivity over other 5-HT and dopamine receptors. At higher concentrations, BRL 54443 induces 5-HT2A-mediated contraction of mouse thoracic aorta strips in vitro (pEC50 = 6.5).{33347} It significantly reduces formalin-induced pain in rat hind paw.{33345}
Brand:CaymanSKU:21263 -Out of stock
BRL 54443 is a potent agonist of the serotonin (5-HT) receptor subtypes 5-HT1E and 5-HT1F (Ki values are 1.1 and 0.7 nM, respectively).{33346} It displays more than 30-fold selectivity over other 5-HT and dopamine receptors. At higher concentrations, BRL 54443 induces 5-HT2A-mediated contraction of mouse thoracic aorta strips in vitro (pEC50 = 6.5).{33347} It significantly reduces formalin-induced pain in rat hind paw.{33345}
Brand:CaymanSKU:21263 -Out of stock
Bromacil is a phytotoxic herbicide that inhibits growth of watermelon, molokhia, and wheat plants (EC50s = 4.77, 0.08, and 3.08 mg/kg of soil, respectively).{42203} It inhibits growth of mustard, pea, sugar beet, linseed, barley, maize, ryegrass, and buckwheat plants by greater than 90% when used at a concentration of 1 kg/hectare.{42204} In vivo, bromacil induces formation of thyroid tumors in rats and liver tumors in mice.{42197}
Brand:CaymanSKU:24136 - 100 mgAvailable on backorder
Bromadiolone is a second generation anticoagulant rodenticide and 4-hydroxycoumarin derivative.{45454,45455} It is an inhibitor of vitamin K epoxide reductase (VKOR) that inhibits blood clotting. It inhibits human VKOR complex subunit 1 (VKORC1) with an IC50 value of 1.6 nM in a cell-based assay.{45456} Bromadiolone is toxic to rodents, including mice (LD50 = 1.75 mg/kg) and rats (LD50s = 1.05 and 1.83 mg/kg for males and females, respectively).{45461,45462} It does not significantly affect breeding performance in mice when administered at a dose of up to 70% of the LD50 value.{45463} Resistance to bromadiolone is conferred by mutations to the VKOR gene, Vkorc1.{45464} Formulations containing bromadiolone have been used in the control of rodent pest populations.
Brand:CaymanSKU:26854 - 100 mgAvailable on backorder
Bromadiolone is a second generation anticoagulant rodenticide and 4-hydroxycoumarin derivative.{45454,45455} It is an inhibitor of vitamin K epoxide reductase (VKOR) that inhibits blood clotting. It inhibits human VKOR complex subunit 1 (VKORC1) with an IC50 value of 1.6 nM in a cell-based assay.{45456} Bromadiolone is toxic to rodents, including mice (LD50 = 1.75 mg/kg) and rats (LD50s = 1.05 and 1.83 mg/kg for males and females, respectively).{45461,45462} It does not significantly affect breeding performance in mice when administered at a dose of up to 70% of the LD50 value.{45463} Resistance to bromadiolone is conferred by mutations to the VKOR gene, Vkorc1.{45464} Formulations containing bromadiolone have been used in the control of rodent pest populations.
Brand:CaymanSKU:26854 - 50 mgAvailable on backorder
Bromamphenicol is a dibrominated derivative of the antibiotic chloramphenicol.{42777} It inhibits rat liver mitochondrial and E. coli protein synthesis by 90.6 and 98.8%, respectively, when used at a concentration of 93 μM, and inhibits DNA synthesis in human lymphoblastoid cells by 83% at 1 mM. Bromamphenicol can also bind to the major adhesin subunit DraE from E. coli.{42778}
Brand:CaymanSKU:28016 - 25 mgAvailable on backorder
Bromamphenicol is a dibrominated derivative of the antibiotic chloramphenicol.{42777} It inhibits rat liver mitochondrial and E. coli protein synthesis by 90.6 and 98.8%, respectively, when used at a concentration of 93 μM, and inhibits DNA synthesis in human lymphoblastoid cells by 83% at 1 mM. Bromamphenicol can also bind to the major adhesin subunit DraE from E. coli.{42778}
Brand:CaymanSKU:28016 - 5 mgAvailable on backorder
Bromantane (Item No. 24688) is an analytical reference standard categorized as a stimulant.{41806} Stimulants, including bromantane, have been used to enhance physical performance in athletes. This product is intended for research and forensic applications.
Brand:CaymanSKU:24688 - 10 mgAvailable on backorder
Bromantane (Item No. 24688) is an analytical reference standard categorized as a stimulant.{41806} Stimulants, including bromantane, have been used to enhance physical performance in athletes. This product is intended for research and forensic applications.
Brand:CaymanSKU:24688 - 25 mgAvailable on backorder
Bromazolam (Item No. 22665) is an analytical reference standard categorized as a benzodiazepine. This product is intended for research and forensic applications.
Brand:CaymanSKU:22665 -Out of stock
Bromazolam (Item No. 22665) is an analytical reference standard categorized as a benzodiazepine. This product is intended for research and forensic applications.
Brand:CaymanSKU:22665 -Out of stock
Bromelain is a mixture of proteolytic enzymes and non-protease components (phosphatases, glucosidases, peroxidases, cellulases, glycoproteins, and carbohydrates) derived from the stem and fruit of pineapple plants.{30808,30809} Bromelain has been studied for a number of potentially beneficial effects, including anti-inflammatory, anti-thrombotic, fibrinolytic, and anti-cancer functions.{30808,30809}
Brand:CaymanSKU:-Available on backorder
Bromelain is a mixture of proteolytic enzymes and non-protease components (phosphatases, glucosidases, peroxidases, cellulases, glycoproteins, and carbohydrates) derived from the stem and fruit of pineapple plants.{30808,30809} Bromelain has been studied for a number of potentially beneficial effects, including anti-inflammatory, anti-thrombotic, fibrinolytic, and anti-cancer functions.{30808,30809}
Brand:CaymanSKU:-Available on backorder
Bromelain is a mixture of proteolytic enzymes and non-protease components (phosphatases, glucosidases, peroxidases, cellulases, glycoproteins, and carbohydrates) derived from the stem and fruit of pineapple plants.{30808,30809} Bromelain has been studied for a number of potentially beneficial effects, including anti-inflammatory, anti-thrombotic, fibrinolytic, and anti-cancer functions.{30808,30809}
Brand:CaymanSKU:-Available on backorder
Bromelain is a mixture of proteolytic enzymes and non-protease components (phosphatases, glucosidases, peroxidases, cellulases, glycoproteins, and carbohydrates) derived from the stem and fruit of pineapple plants.{30808,30809} Bromelain has been studied for a number of potentially beneficial effects, including anti-inflammatory, anti-thrombotic, fibrinolytic, and anti-cancer functions.{30808,30809}
Brand:CaymanSKU:-Available on backorder
Bromfenac is an inhibitor of cyclooxygenase 2 (COX-2; IC50 = 6.6 nM) that is selective over COX-1 (IC50 = 210 nM).{39441} It inhibits prostaglandin E2 (PGE2; Item No. 14010) production in a rabbit model of LPS-induced eye inflammation. Bromfenac also decreases inflammation following cataract removal in dogs when administered as a 0.9% topical solution on a tapering schedule for 24 weeks.{39440} Formulations containing bromfenac have been used in the treatment of postoperative inflammation following cataract surgery.
Brand:CaymanSKU:23763 - 10 mgAvailable on backorder
Bromfenac is an inhibitor of cyclooxygenase 2 (COX-2; IC50 = 6.6 nM) that is selective over COX-1 (IC50 = 210 nM).{39441} It inhibits prostaglandin E2 (PGE2; Item No. 14010) production in a rabbit model of LPS-induced eye inflammation. Bromfenac also decreases inflammation following cataract removal in dogs when administered as a 0.9% topical solution on a tapering schedule for 24 weeks.{39440} Formulations containing bromfenac have been used in the treatment of postoperative inflammation following cataract surgery.
Brand:CaymanSKU:23763 - 50 mgAvailable on backorder
Bromo-DragonFLY is a difuran analog of the Schedule I hallucinogen 4-bromo-2,5-dimethoxyphenethylamine.{21377} This designer drug strongly binds serotonin receptors (Ki = 0.04, 0.19, and 0.02 nM for 5-HT2A, 5-HT2B, and 5-HT2C, respectively).{21685} It is more potent than LSD in drug discrimination studies in rats.{21685} Related to its high potency, Bromo-DragonFLY has been associated with fatalities as well as acute intoxications.{21684} GC-MS, GC-IRD, and solid phase FTIR spectra have been published.{21377} This product is intended for research and forensic purposes.
Brand:CaymanSKU:11561 - 1 mgAvailable on backorder
Bromo-DragonFLY is a difuran analog of the Schedule I hallucinogen 4-bromo-2,5-dimethoxyphenethylamine.{21377} This designer drug strongly binds serotonin receptors (Ki = 0.04, 0.19, and 0.02 nM for 5-HT2A, 5-HT2B, and 5-HT2C, respectively).{21685} It is more potent than LSD in drug discrimination studies in rats.{21685} Related to its high potency, Bromo-DragonFLY has been associated with fatalities as well as acute intoxications.{21684} GC-MS, GC-IRD, and solid phase FTIR spectra have been published.{21377} This product is intended for research and forensic purposes.
Brand:CaymanSKU:11561 - 10 mgAvailable on backorder
Bromo-DragonFLY is a difuran analog of the Schedule I hallucinogen 4-bromo-2,5-dimethoxyphenethylamine.{21377} This designer drug strongly binds serotonin receptors (Ki = 0.04, 0.19, and 0.02 nM for 5-HT2A, 5-HT2B, and 5-HT2C, respectively).{21685} It is more potent than LSD in drug discrimination studies in rats.{21685} Related to its high potency, Bromo-DragonFLY has been associated with fatalities as well as acute intoxications.{21684} GC-MS, GC-IRD, and solid phase FTIR spectra have been published.{21377} This product is intended for research and forensic purposes.
Brand:CaymanSKU:11561 - 5 mgAvailable on backorder
Bromoacetamido-PEG3-Boc-amine is a PEGylated linker that contains a tert-butyloxy carbonyl (Boc) protecting group.
Brand:CaymanSKU:30554 - 100 mgAvailable on backorder
Bromoacetamido-PEG3-Boc-amine is a PEGylated linker that contains a tert-butyloxy carbonyl (Boc) protecting group.
Brand:CaymanSKU:30554 - 250 mgAvailable on backorder
Bromoacetamido-PEG3-Boc-amine is a PEGylated linker that contains a tert-butyloxy carbonyl (Boc) protecting group.
Brand:CaymanSKU:30554 - 50 mgAvailable on backorder
Bromobenzene-13C6 is a building block.{56010,56011} It has been used in the synthesis of 13C6-labeled naphthalenes and polychlorinated biphenyls.
Brand:CaymanSKU:30524 - 1 gAvailable on backorder
Bromobenzene-13C6 is a building block.{56010,56011} It has been used in the synthesis of 13C6-labeled naphthalenes and polychlorinated biphenyls.
Brand:CaymanSKU:30524 - 100 mgAvailable on backorder